VCEL — Vericel Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 887359 ·
Last close
$57.88
Market Cap
$2.95B
52W High
$59.75
52W Low
$28.95
ADV30
809,970
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 85,371,000 | 62,610,000 | 12,186,000 | 14,161,000 | 517,110,000 | 133,493,000 | 132,938,000 |
| Jun 2026 | 77,457,000 | 56,402,000 | 434,000 | 2,206,000 | 502,866,000 | 125,358,000 | 132,825,000 |
| Mar 2026 | 68,425,000 | 49,266,000 | -8,064,000 | -6,302,000 | 485,627,000 | 109,295,000 | 129,396,000 |
| Dec 2025 | 92,918,000 | 73,128,000 | 22,415,000 | 23,243,000 | 487,969,000 | 100,092,000 | 133,329,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$69,670,000
Investing CF
$-26,788,000
Financing CF
$1,944,000
CapEx
$-8,006,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.47
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-380,393,000
Inventory
$18,382,000
Receivables
$75,712,000
ST Investments
$37,100,000
EBIT TTM
$25,720,000
Pretax Income TTM
$25,080,000
Interest Exp TTM
$640,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$324,171,008
EBITDA
$40,573,000
Free Cash Flow
$49,890,624
Enterprise Value
$2,708,124,928
Total Cash
$170,268,000
Total Debt
$91,147,000
Shares Out
51,029,770
Trailing EPS
$0.64
Book Value
$7.53
ROE
9.4%
ROA
3.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 276,259,000 | 11,044,000 | 16,518,000 | 487,969,000 | 133,329,000 | 354,640,000 | 51,910,000 |
| Dec 2024 | 237,224,000 | 4,519,000 | 10,362,000 | 432,722,000 | 140,755,000 | 291,967,000 | 58,163,000 |
| Dec 2023 | 197,516,000 | -6,464,000 | -3,182,000 | 353,657,000 | 127,705,000 | 225,952,000 | 35,311,000 |
| Dec 2022 | 164,365,000 | -17,058,000 | -16,709,000 | 273,003,000 | 80,731,000 | 192,272,000 | 17,687,000 |
TTM Snapshot
Revenues TTM
$306,303,000
NetIncome TTM
$24,221,000
OpCashFlow TTM
—
Assets (Latest)
$502,866,000
Forward EPS
$0.85
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $58.65 · call volume: 80 · put volume: 6
Expected Move to 2027-01-15:
±$8.10
(13.81%) —
implied range
$50.55 –
$66.75
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | $2.89B | $18.00 | — |
| ADMA | ADMA BIOLOGICS, INC. | $3.02B | $13.63 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.48B | $7.53 | — |
| RLAY | Relay Therapeutics, Inc. | $3.64B | $16.47 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.86B | $78.20 | — |
News headlines (Yahoo Finance, 1h cache)
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
2026-11-13 13:30 · Yahoo
Earnings Estimates Moving Higher for Vericel (VCEL): Time to Buy?
2026-11-10 19:40 · Yahoo
Vericel (VCEL) Jumped, What Is Behind The Move?
2026-11-07 00:18 · Yahoo
Vericel Q3 Earnings Call Highlights
2026-11-06 20:14 · Yahoo
Vericel Corp (VCEL) (Q3 2026) Earnings Call Highlights: Record Revenue and Tripled Net Income ...
2026-11-05 23:19 · Yahoo
Vericel Corp (VCEL) Q3 2026 Earnings Call Transcript
2026-11-05 19:49 · Yahoo
Vericel (VCEL) Stock Looks Overvalued Given Its Earnings Support
2026-11-05 14:11 · Yahoo
Vericel Corporation (VCEL) Beats Q3 Earnings and Revenue Estimates
2026-11-05 13:35 · Yahoo
Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
2026-11-05 12:55 · Yahoo
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
2026-10-22 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.